{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidool47qhmvnamzedgtd3ovdkzbgmxujqkv3bg3te5tsf6pakykjm",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mfrzxyd7k6j2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreifz2jpvehfu7qextifkawzfc37s5jirq5hcqcsdqqdy6pnadw5wpa"
    },
    "mimeType": "image/jpeg",
    "size": 441937
  },
  "path": "/news/2026-02-sensitive-cell-therapy-solid-cancers.html",
  "publishedAt": "2026-02-26T15:20:03.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Immunology"
  ],
  "textContent": "CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers. Columbia researchers have now found that a new type of cell therapy—HIT cells, a cousin to CAR T with enhanced sensitivity—overcomes a major obstacle to treating solid tumors with cell therapy and can completely eliminate kidney, pancreatic, and ovarian cancers in mice. The research appears in the journal Science.",
  "title": "More sensitive HIT cell therapy shows promise against solid cancers"
}